Next-generation treatment protects against progression in some patients with advanced breast cancer
Imlunestrant, an investigational next-generation selective estrogen receptor degrader (SERD), improved progression-free survival in patients with endocrine therapy-pretreated, ER-positive, HER2-negative advanced breast cancer—as monotherapy in patients with ESR1 mutations and as combination therapy with abemaciclib (Verzenio) in all patients,